AbCellera Biologics (ABCL) Tmuɣli n wazal
Ṛṛbem n lḥedd$12.72Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel+0.47%
Asnulfu n AI: ABCL
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
AbCellera Biologics Inc. operates as a pharmaceutical company. The company researches and develops next-generation therapeutic antibodies using a combination of technologies, including patented immunizations, microfluidics, high-throughput imaging, genomics, computing, and laboratory automation. AbCellera Biologics serves customers in Canada.
